Lesson plan
Nolasiban
Nolasiban ( ; developmental code names OBE001 and RPN-002), also known previously as erlosiban, is an oxytocin receptor antagonist which is under development for the treatment of female infertility and adenomyosis. It was also under development for the treatment of preterm labor, but development for this indication was discontinued. The drug is a small molecule or non-peptide and is taken orally. The drug interacts with both the oxytocin receptor (K i = 52 nM; = 81 nM) and the vasopressin V 1A receptor (K i = 120 nM), whereas findings for the vasopressin V 2 receptor were not reported. It is of relatively low potency, being used and studied clinically at doses of 900 to 2,400 mg orally. Nolasiban was first described in the scientific literature by 2015. It was originated by Merck Serono and is under development by ObsEva and ReproNovo. As of July 2026, the drug is in phase 2 clinical trials for female infertility and phase 1 trials for adenomyosis. It was also previously in phase 3 trials in the late 2010s.
Article summary
Nolasiban ( ; developmental code names OBE001 and RPN-002), also known previously as erlosiban, is an oxytocin receptor antagonist which is under development for the treatment of female infertility and adenomyosis. It was also under development for the treatment of preterm labor, but development for this indication was discontinued. The drug is a small molecule or non-peptide and is taken orally. The drug interacts with both the oxytocin receptor (K i = 52 nM; = 81 nM) and the vasopressin V 1A receptor (K i = 120 nM), whereas findings for the vasopressin V 2 receptor were not reported. It is of relatively low potency, being used and studied clinically at doses of 900 to 2,400 mg orally. Nolasiban was first described in the scientific literature by 2015. It was originated by Merck Serono and is under development by ObsEva and ReproNovo. As of July 2026, the drug is in phase 2 clinical trials for female infertility and phase 1 trials for adenomyosis. It was also previously in phase 3 trials in the late 2010s.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.